Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Tozuka T, Noro R, Yoshida K, Takahashi S, Hirao M, Matsuda K, Kato Y, Nakamichi S, Takeuchi S, Matsumoto M, Miyanaga A, Kunugi S, Honda K, Adachi J, Seike M. Tozuka T, et al. Among authors: miyanaga a. JTO Clin Res Rep. 2024 Mar 21;5(4):100668. doi: 10.1016/j.jtocrr.2024.100668. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38646155 Free PMC article.
CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
Fukuizumi A, Noro R, Seike M, Miyanaga A, Minegishi Y, Omori M, Hirao M, Matsuda K, Kunugi S, Nishiwaki K, Morimoto M, Motohashi H, Ohwada H, Usuda J, Gemma A. Fukuizumi A, et al. Among authors: miyanaga a. JTO Clin Res Rep. 2021 Sep 24;2(11):100232. doi: 10.1016/j.jtocrr.2021.100232. eCollection 2021 Nov. JTO Clin Res Rep. 2021. PMID: 34746885 Free PMC article.
Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC.
Terashima Y, Matsumoto M, Iida H, Takashima S, Fukuizumi A, Takeuchi S, Miyanaga A, Terasaki Y, Kasahara K, Seike M. Terashima Y, et al. Among authors: miyanaga a. JTO Clin Res Rep. 2023 Sep 21;4(11):100578. doi: 10.1016/j.jtocrr.2023.100578. eCollection 2023 Nov. JTO Clin Res Rep. 2023. PMID: 37885809 Free PMC article.
Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.
Nakamichi S, Seike M, Miyanaga A, Chiba M, Zou F, Takahashi A, Ishikawa A, Kunugi S, Noro R, Kubota K, Gemma A. Nakamichi S, et al. Among authors: miyanaga a. Oncotarget. 2018 Jun 5;9(43):27242-27255. doi: 10.18632/oncotarget.25531. eCollection 2018 Jun 5. Oncotarget. 2018. PMID: 29930762 Free PMC article.
Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
Nishima S, Miyanaga A, Saito S, Yuasa M, Takahashi S, Kashiwada T, Sugano T, Noro R, Minegishi Y, Terasaki Y, Saito Y, Kubota K, Seike M, Gemma A. Nishima S, et al. Among authors: miyanaga a. Intern Med. 2021 Feb 15;60(4):591-594. doi: 10.2169/internalmedicine.5435-20. Epub 2020 Sep 30. Intern Med. 2021. PMID: 32999231 Free PMC article.
148 results